2005.06.28. dr. pogány - who, pretoria 1/59 supplementary training workshop on good manufacturing...
TRANSCRIPT
![Page 1: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/1.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 1/59
Supplementary Training Workshop on Good Manufacturing Practices (GMP)
MANUFACTURING PROCESS VALIDATION
Solid Dosage Forms
János Pogány, pharmacist, PhD, consultant to WHO
Pretoria, South Africa, 28 June 2005E-mail: [email protected]
![Page 2: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/2.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 2/59
WHO GMP and related guides WHO good manufacturing practices (GMP):
main principles for pharmaceutical products Section 4. Qualification and validation
Supplementary guidelines on good manufacturing practices (GMP): Validation (2003) – Draft.
![Page 3: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/3.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 3/59
WHO GMP and related guides WHO good manufacturing practices: main principles
for pharmaceutical products – Validation of manufacturing processes Good manufacturing practices for pharmaceutical
products. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second report. Geneva, World Health Organization, 1992:14–79 (WHO Technical Report Series, No. 823).
![Page 4: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/4.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 4/59
ICH guidelines PHARMACEUTICAL DEVELOPMENT, Q8,
Draft ICH Consensus Guideline, Released for Consultation on 18 November 2004, at Step 2 of the ICH Process
QUALITY RISK MANAGEMENT, Q9, Draft ICH Consensus Guideline, Released for Consultation on 22 March 2005, at Step 2 of the ICH Process
![Page 5: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/5.jpg)
PROSPECTIVE VALIDATION
Pharmaceutical DevelopmentLaboratory scale R + D
![Page 6: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/6.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 6/59
Physicochemical and physical properties of API
Physicochemical
hygroscopicity
solubility
water content
polymorphism
permeability
Physical
particle size
bulk density (g/100ml)
flowability
color, olor, taste
consistency
![Page 7: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/7.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 7/59
Equilibrium Moisture ContentAt relative humidities (RHs) <100%, a solid API (that does not form crystalline compounds with water) will loose some bound and all its unbound water until it is in equilibrium with the surrounding atmosphere. The sum of both these moistures is the free moisture of the API (granules) at the specified RH.
![Page 8: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/8.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 8/59
Rate of Water Absorption at Different RHs
0,20
0,25
0,30
0,35
0,40
0,451 4 7 10 13 16 19 22 25 28
Lg time, t (3 min. units)
Lg
RH
, %
35%
55%
75%
100%
![Page 9: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/9.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 9/59
Solubility of Zidovudine at 25oCpH Dissolved material (mg/ml)
3.0 21
4.0 20
5.3 20
6.0 21
7.0 22
Distilled water 20
8.0 21
![Page 10: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/10.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 10/59
Solubility of Artesunate
pH Dissolved API (mg/ml)
1 1,9
5 1,5
6 3,5
7 10,2
8 12,2
![Page 11: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/11.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 11/59
Decomposition of Artesunatein aqueous solution
Solvent Time (h) Decomposition (%)
Water 2 0
0.1N HCl 2 74
0.1N NaOH 2 100
![Page 12: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/12.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 12/59
Relationship between Permeability Coefficient and Octanol-Water Partition
1 Prednisolone
...
3 Dexamethazone
...
9 Dexamethazone-acetate
...
11 Progesterone
![Page 13: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/13.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 13/59
NORVIR (Ritonavir) EPAR/CPMP /527/96
1. No polymorphism observed at the time of first submission (only form I : hard capsules and oral solution registered)
2. Failure in dissolution during stability studies for hard capsules
3. Emergence of form II (contamination of form I)
4. Production of hard capsules discontinued
5. Development and registration of soft capsules
![Page 14: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/14.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 14/59
Particle SizeWhen the solubility of an API is less than 0.1 mg/ml, the optimization of the particle size during preformulation may be critical to efficacy or pharmaceutical equivalence. Other researchers believe that particle size may be critical at a solubility of 1 mg/ml or less.
![Page 15: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/15.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 15/59
Effect of Particle Size on Dissolution of Nevirapine tablets
USP Type II / 0.01N HCl 50 RPM / 900 ml
0
20
40
60
80
100
120
Time (Min)Nevipan MGS(1024)05 (90%LT81.12)Nevipan MGS(1024)60B (90%LT30.89)Viramune 992633B
0 10 20 300.00 50.80 73.80 83.980.00 80.00 92.00 96.000.00 83.30 96.60 97.70
% D
rug
Dis
solv
ed
![Page 16: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/16.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 16/59
Screening of Compositions
Compatibility of an API with the excipients and the APIs with each other in FDCs is studied in open system stress stability experiments, e.g., 60-80 oC, 100% RH.
Regulatory stability studies of the final composition are frequently initiated in the pharmaceutical R + D laboratory.
![Page 17: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/17.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 17/59
Compatibility of Acetylsalicylic Acid with Excipients
Time (week) Talc A Talc B
Salicylic acid, % Salicylic acid, %
0 0.10 0.10
4 0.32 5.85
8 0.41 13.00
12 0.80 28.50
![Page 18: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/18.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 18/59
Triomune - WHOPARExperimental „studies showed chemical incompatibility for the lamivudine with stavudine and nevirapine with stavudine combination. Lamivudine with nevirapine showed no change indicating that they are compatible. Stavudine was found incompatible with both the drugs, indicated by the brown colouration and increase in the impurities.
Therefore it was decided to separate stavudine from the other two drugs. Hence the formulation was proposed to be bilayered tablet formulation, where stavudine is in one layer and lamivudine + nevirapine in other layer. Thus contact of stavudine with the other two drugs was minimised.”
![Page 19: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/19.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 19/59
Dissolution Test and Profile A (discriminating) dissolution test method should
be developed for the final composition of the FPP. Limits should be set for each API in fixed-dose
FPPs. The dissolution method should be incorporated into
the stability and quality control programs. Multipoint dissolution profiles of both the test and
the reference FPPs should be compared.
![Page 20: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/20.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 20/59
Dissolution Profile of Viramune and Generic Nevirapine Tablets on the Indian Market
USP Type II / 0.01N HCl 50 RPM / 900 ml
0
20
40
60
80
100
120
Time (Min)Viramune B.No.992633BBrand C B.No.C00139Ranbaxy B.No.(1024)17
0 10 20 30 450.0 83.3 96.6 97.7 99.70.0 34.3 51.3 61.2 70.80.0 88.9 97.6 99.2 99.7
% D
rug
Dis
so
lve
d
F2
20
73
![Page 21: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/21.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 21/59
Hypothetical Dissolution Profile of a 2-FDC FPP
020406080
100120
0 15 30 45 60
minutes
% d
isso
lved Series1
Series2
Series3
Series4
![Page 22: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/22.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 22/59
Pivotal BatchesA tabulated summary of the compositions of the clinical, bioequivalence, stability and validation FPP batches together with documentation (batch number, batch size, manufacturing date and certificate of analysis at batch release) and a presentation of dissolution profiles must be provided.
Results from comparative in vitro studies (e.g., dissolution) or comparative in vivo studies (e.g., bioequivalence) should be discussed when appropriate.
![Page 23: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/23.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 23/59
Excipients – Lactose (L)Different grade, different physical properties: Angle of repose: 32- 47o (Specs.) Bulk density: 0.34 – 0.80 g/cm3 (Specs.) Bulk density (tapped): 0.41 – 0.95 g/cm3
Flowability (spray processed): 4.1 g/s (Specs.) Hygroscopicity: L monohydrate is stable in air at room
temperature. Anhydrous L may absorb humidity.
Moisture content: L monohydrate contains approx. 5% w/w water of crystallization
![Page 24: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/24.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 24/59
Excipients – Lactose (L)Solubility in water 1 in 4.63 at 25 oC 1 in 3.14 at 40 oC 1 in 2.04 at 50 oC 1 in 1.68 at 60 oC 1 in 1.07 at 80 oC
Particle size distribution: depends on grade.
Stability: may develop brown colouration (≥ 80% RH)
Incompatibility: APIs with a primary amine group (base catalysed), aminophylline and amphetamines.
![Page 25: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/25.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 25/59
Surface of a film-coated tablets containing a high level of a superdisintegrant
![Page 26: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/26.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 26/59
Packaging Materials Moisture-impermeable containers: glass ampoules,
vials closed with rubber stoppers and fixed with metal caps, aluminium/aluminium blisters, high density polyethylene (HDPE) or glass bottles fitted with metal metal or HDPE closures, etc.
Moisture-permeable containers: polyvinyl chloride (PVC) blisters, low density polyethylene (LDPE) bottles, HDPE bottles fitted with polypropylene closures.
Specifications of packaging materials should include thickness and permeability coefficient.
![Page 27: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/27.jpg)
CONCURRENT VALIDATION
Commitment Batches
![Page 28: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/28.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 28/59
Technical pharmacy Pharmaceutical production system
(from purchasing API to packaging FP) Utility support system (HVAC, water, HPLC, etc.
equipment containing many items) Process (tablet making) (Unit) operation (granulation, compression) Step (sifting, sizing) Procedure, method, technique (SOP)
![Page 29: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/29.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 29/59
Causes of variation Man (different operators - lack of proper training)
Machine / equipment (variation of tablet weight)
Measurement (lack of calibration)
Method (validated manufacturing methods)
Material (batch-to-batch variation of the same crystal
form – different crystal forms (ASA)]
Environment (OoS T and RH in capsule filling)
![Page 30: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/30.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 30/59
4.10 Scientific approach „Processes and procedures should be established on the basis
of the results of the validation performed.”
Objectives To prove that the tests, measurements, results and
interpretation of formal studies on (manufacturing) processes and procedures/methods are appropriate and accurate.
To stabilize new processes (to reduce variability, to increase batch to batch consistency of quality attributes of products).
To reduce defect levels (standardize yields). To reduce production costs.
![Page 31: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/31.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 31/59
Process approachCONTINUOUS IMPROVEMENT OF THE QUALITY MANAGEMENT SYSTEM
CUSTOMER
REQUIREMENTS
CUSTOMER
SATISFACTION
Management responsibility
Resourcemanagement
Monitoring,improvement
Manufacture ProductInputs
![Page 32: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/32.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 32/59
Measure of variation (spread of data)
95.46%68.26%
![Page 33: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/33.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 33/59
Mean (average) chart
Normal variation
due to common causes
UCL Upper control limit
LCL Lower control limit
Abnormal variation of process – special causes
Abnormal variation of process – special causes
average = mean
![Page 34: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/34.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 34/59
Process capability index, Cpacceptance limits UCL - LCL
Cp = = process capability 6σ*
6σ*Three sigma: Cp = = 1
6σ*
12σ*Six sigma: Cp = = 2
6σ*
σ* ... is the measured standard deviation of the process
![Page 35: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/35.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 35/59
Process capability index, Cpk UCL - x
Cpk = 3σn
UCL ... upper control limit x ... mean of the acceptance criteria, target value σn ... is 50% of the measured standard deviation of the process
Cpk shows the closeness of the process mean to the target value.
![Page 36: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/36.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 36/59
Output of processes for differentCpk indices
nσn = 3σ UCL Cpk No. of products OoS (ppm)
1σ1 m + σ1-0.166 691 464
2σ2 m + 2σ20.166 308 536
3σ3 m + 3σ30.5 66 807
4σ4 m + 4σ40.833 6 210
5σ5 m + 5σ51.166 233
6σ6 m + 6σ61.5 3.4
![Page 37: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/37.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 37/59
Objective and result of process control
1.The process reveals serious risks and it is not controlled
2.The process is not yet controlled but acceptance criteria are met
3.The process is under control and the product has a consistently high quality
UCL
N
LCL
UCL
N
LCL
UCL
N
LCL
![Page 38: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/38.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 38/59
Process under control Most points fall near the central line (68% within
one σ) A few points fall near the control limits (5% in
the third σ) Points shold balance on both sides of the mean Points should cross the mean line often. Points should show a random pattern (no trends,
cycles, clustering)
![Page 39: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/39.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 39/59
4.8-4.9 Protocols and reports Validation studies are an essential part of GMP
and should be conducted in accordance with predefined and approved protocols.
A written report summarizing the results recorded and the conclusions reached should be prepared and stored.
![Page 40: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/40.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 40/59
Process validation protocol/report
Short description of the process with a summary of the critical processing steps or critical parameters to be monitored during validation.
Additional testing intended to be carried out (e.g. with proposed acceptance criteria and analytical validation as appropriate).
Sampling plan — where, when, how and how many samples are taken.
Details of methods for recording and evaluation of results.
![Page 41: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/41.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 41/59
Illustrative variables of wet granulationProcess step Control or manipulate
(independent) variablesMeasured responses or output (dependent) variables
CrystallizationMicronization
Particle sizeBulk density
Dissolution timeGranulation and granule variables
Pre-mixing Speed, time, order of addition
Blend uniformity
Wet kneading Batch (load) sizeSpeed Impeller Chopper Spraying rateVolume of binder solutionGranulation time
End-point amperage Impeller Chopper Additional solvent volume
![Page 42: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/42.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 42/59
Illustrative variables of wet granulationProcess step Control or manipulate
(independent) variablesMeasured responses or output (dependent) variables
Drying Inlet air temperature (seasonal variation)Drying time (seasonal variation)Cooling time (if applicable)
Outlet air temperatureLODMoisture content
Sizing Screen type and size
Feed rate
Granule size distribution (variation of sub-batches)
Blending Batch size (sub-batches)SpeedBlending time
Blend uniformityBulk density untapped tappedFlowabilityYield
![Page 43: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/43.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 43/59
Indentation hardness profiles for tablets of different shape
Flat Shallow convex Standard convex Deep convex Ball-shaped
![Page 44: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/44.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 44/59
Areas most prone to surface erosion for flat, shallow convex, caplet-shaped and deep convex
tablets
![Page 45: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/45.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 45/59
Erosion on the surface of the tablet with a logo
![Page 46: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/46.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 46/59
Twinning during the coating process for flat-faced and caplet shaped tablets
![Page 47: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/47.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 47/59
Measurement points of film thickness across the tablet surfaces
FACE EDGE
SIDE
![Page 48: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/48.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 48/59
Illustrative variables of compression and film-coating
Process step Control or manipulate (independent) variables
Measured responses or output (dependent) variables
Compression
Machine speedGranule feed ratePrecompression forceCompression forcePunches and dies
Weight variationContent uniformityFriabilityHardnessThicknessDisintegrationDissolution time and profileYield
Film-coating Inlet air temperature
Inlet air flow
Spray rate
Spray atomizing pressure
Outlet air temperature
Tablet-bed temperature
Coat quality
Yield
![Page 49: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/49.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 49/59
Illustrative variables of tablet packagingProcess step Control or manipulate
(independent) variablesMeasured responses or output (dependent) variables
Blistering Machine speedMachinability of blister materialForming temperatureForming pressureSealing temperatureSealing pressure
Leak testingAppearanceMinimum information is legibleYield
Bulk packing
Tablet counter
Incomplete tablets
Machine speed
Number of tablets
Detection, counting
Pilfer-proof
Labeling
Yield
![Page 50: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/50.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 50/59
4.10 Scientific approach Processes and procedures should be established
on the basis of the results of the validation performed.
![Page 51: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/51.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 51/59
Commitment (validation) batches Process validation reports should be submitted in the
application for prequalification. Formal studies of production scale batches (not less
than three) are required to identify the critical variables.
Provisional equipment control parameters and the corresponding in-process acceptance criteria must be deduced from the results of experiments with the validation batches.
Critical parameters are to be monitored, non-critical ones should be tested occasionally.
![Page 52: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/52.jpg)
RETROSPECTIVE VALIDATION
Annual Product Review
![Page 53: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/53.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 53/59
Annual FPP quality review (1) Starting materials used in the product, especially those
from new sources. Critical in-process controls and finished product results. All batches that failed to meet established specification(s). All critical deviations or non-conformances and related
investigations. All changes carried out to the processes or analytical
methods. Marketing Authorisation variations submitted, or granted,
or refused, including those for third country dossiers.
![Page 54: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/54.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 54/59
Annual FPP quality review (2) Results of the stability monitoring programme. All quality-related returns, complaints and recalls,
including export only medicinal products. Adequacy of previous corrective actions. For new marketing authorisations, a review of post-
marketing commitments. A list of validated procedures and their revalidation
dates. A list of qualified equipment, support utility systems
and their requalification dates, including calibration programmes.
![Page 55: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/55.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 55/59
Case summary of 20 batches (1)Statistics Av. wt. mg Dissolution % Assay %
Mean 347,6 99,6 98,2
Median 346,9 100,0 97,5
SD 5,2 2.5 2.2
Range 22.3 10.0 8.8
Minimum 337.0 95.6 95.0
Maximum 359.3 105.6 103.8
Conf. level, 95% 2.4 1.3 1.0
Accept. Crit. 350±5% 75%, 40' 90-110
![Page 56: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/56.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 56/59
Case summary of 20 batches (2)
1. Acceptance criteria for assay and dissolution
rate are loose and should be tightened.
2. Potentially critical impurities are not tested.
3. IPC data are not included in the retrospective
analysis of batch records.
![Page 57: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/57.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 57/59
BEST PROCESS
MINIMUM REQUIRED INPUT
MAXIMUM OUTPUT
AT NO COST TO SOCIETY (industrial safety, labour safety, internal and external environment protection)
![Page 58: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/58.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 58/59
COSTS OF QUALITYVisible costs, e.g., waste and returned goods
Hidden costs, e.g., wrong decisions, non-competitive manufacturing process,low yield, maintenance, idle machine time, workers attitude, etc.
![Page 59: 2005.06.28. Dr. Pogány - WHO, Pretoria 1/59 Supplementary Training Workshop on Good Manufacturing Practices (GMP) MANUFACTURING PROCESS VALIDATION Solid](https://reader035.vdocuments.site/reader035/viewer/2022062404/551aa8e255034656628b4b05/html5/thumbnails/59.jpg)
2005.06.28. Dr. Pogány - WHO, Pretoria 59/59
Main points again Manufacturing methods are the same in the
innovative and generic industries. Pharmaceutical development is a major source of
early identification of critical product and process parameters.
Validation batches should be tested extensively to establish preliminary/tentative IPC parameters.
Annual product review results in continuous improvement of products and processes.